Comorbidity in bullous pemphigoid: up-date and clinical implications.
autoimmune skin blistering disease
bullous pemphigoid
comorbidity
inflammatory disease
malignancy
metabolic disease
neurologic disease
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
03
2023
accepted:
19
05
2023
medline:
18
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Bullous pemphigoid is the most common autoimmune blistering disease in industrialized countries and particularly affects the elderly. In this patient population, comorbid diseases are frequent and may complicate management and treatment of bullous pemphigoid. A better understanding why distinct diseases are more frequent in bullous pemphigoid patients may lead to new pathophysiological insights and - as a consequence - result in better patient care. The association of bullous pemphigoid with neurological and psychiatric diseases is well known and confirmed by several case-control studies. Association with further diseases such as malignancy and metabolic diseases are still discussed controversially. In recent years new relationships between bullous pemphigoid and autoimmune as well as inflammatory skin diseases have been reported. This review provides a systematic overview on studies addressing comorbidity in bullous pemphigoid patients. Increasing the awareness of both, common and rare comorbid diseases, may enable clinicians to optimize patient support and individualized treatment of bullous pemphigoid.
Identifiants
pubmed: 37457698
doi: 10.3389/fimmu.2023.1196999
pmc: PMC10346857
doi:
Types de publication
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1196999Informations de copyright
Copyright © 2023 Huttelmaier, Benoit and Goebeler.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Dtsch Dermatol Ges. 2022 Jun;20(6):798-805
pubmed: 35657083
Life (Basel). 2022 Apr 18;12(4):
pubmed: 35455086
J Am Acad Dermatol. 1981 Jun;4(6):695-7
pubmed: 7016941
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2181-2189
pubmed: 35796163
Br J Dermatol. 2009 Jun;160(6):1343-5
pubmed: 19416254
JAMA Dermatol. 2018 Oct 1;154(10):1152-1158
pubmed: 30090931
JAMA Dermatol. 2015 Jun;151(6):665-7
pubmed: 25671805
J Dermatol Sci. 2008 Feb;49(2):153-61
pubmed: 17920818
Dermatol Ther. 2021 Sep;34(5):e15031
pubmed: 34137146
Br J Dermatol. 2017 Jun;176(6):1486-1491
pubmed: 28235244
Arch Dermatol Res. 2020 May;312(4):263-271
pubmed: 31741052
Sci Rep. 2020 Jul 29;10(1):12727
pubmed: 32728039
J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):181-4
pubmed: 8335735
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Acta Dermatovenerol Alp Pannonica Adriat. 2022 Mar;31(1):7-11
pubmed: 35339128
Int J Dermatol. 2018 Jun;57(6):664-669
pubmed: 29630716
J Am Acad Dermatol. 2017 Oct;77(4):691-699
pubmed: 28645646
Arch Dermatol Res. 2014 Jan;306(1):75-80
pubmed: 23912480
J Dermatol Sci. 1996 Feb;11(2):142-7
pubmed: 8869035
Exp Cell Res. 2010 Feb 1;316(3):297-313
pubmed: 19932097
J Dtsch Dermatol Ges. 2022 Oct;20(10):1305-1312
pubmed: 36108333
Stroke. 2011 Feb;42(2):319-23
pubmed: 21164122
J Invest Dermatol. 2015 May;135(5):1445-1447
pubmed: 25560279
Dtsch Arztebl Int. 2021 Jun 18;118(24):413-420
pubmed: 34369370
Front Neurol. 2020 Aug 21;11:851
pubmed: 32973654
Clin Dermatol. 1987 Jan-Mar;5(1):60-3
pubmed: 3552193
Clin Dev Immunol. 2013;2013:240570
pubmed: 23878581
J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1768-1776
pubmed: 29575160
Dermatitis. 2022 Jul-Aug 01;33(4):268-276
pubmed: 34570736
Antibodies (Basel). 2022 Jun 28;11(3):
pubmed: 35892704
J Am Acad Dermatol. 2018 Dec;79(6):1034-1038.e5
pubmed: 29803903
JAMA Dermatol. 2022 Feb 01;158(2):167-175
pubmed: 34964804
Indian J Dermatol Venereol Leprol. 2023 May-Jun;89(3):363-371
pubmed: 36331841
Br J Dermatol. 2012 Sep;167(3):688-91
pubmed: 22486251
Sisli Etfal Hastan Tip Bul. 2018 Dec 28;52(4):302-306
pubmed: 32774095
Acta Derm Venereol. 2005;85(6):560-1
pubmed: 16396820
Dermatology. 2021;237(6):921-928
pubmed: 33640889
Arch Dermatol. 1979 Aug;115(8):988-9
pubmed: 380470
Diabetes Res Clin Pract. 2021 Jan;171:108546
pubmed: 33232759
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1709-1714
pubmed: 28485892
Arch Dermatol Res. 2021 Jul;313(5):327-332
pubmed: 32647978
J Invest Dermatol. 2017 Jan;137(1):71-76
pubmed: 27650606
J Am Acad Dermatol. 2017 Aug;77(2):370-372
pubmed: 28711088
J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1826-1830
pubmed: 35611551
Br J Dermatol. 2013 Sep;169(3):718-9
pubmed: 23607274
J Am Acad Dermatol. 2020 Nov;83(5):1255-1268
pubmed: 32454097
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):981-987
pubmed: 33098720
Lancet. 2013 Jan 26;381(9863):320-32
pubmed: 23237497
Acta Derm Venereol. 2018 Dec 27;99(1):72-77
pubmed: 29963683
An Bras Dermatol. 2014 Mar-Apr;89(2):274-8
pubmed: 24770504
J Dermatolog Treat. 2022 Nov;33(7):2886-2893
pubmed: 35694729
Sci Rep. 2016 Nov 15;6:37125
pubmed: 27845416
Eur J Intern Med. 2016 Jun;31:25-8
pubmed: 26912020
Clin Nephrol. 2000 Feb;53(1 Suppl):S2-8
pubmed: 10746799
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Arch Dermatol Res. 2022 Jan;314(1):77-83
pubmed: 33687539
J Dermatol Sci. 2018 Mar;89(3):258-262
pubmed: 29248402
Front Med (Lausanne). 2020 Aug 31;7:511
pubmed: 32984384
Med J Malaysia. 2015 Apr;70(2):81-5
pubmed: 26162382
Front Immunol. 2021 Oct 14;12:738907
pubmed: 34721404
J Dermatol. 2021 Mar;48(3):317-323
pubmed: 33368562
J Am Acad Dermatol. 2013 Apr;68(4):687-689
pubmed: 23522419
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):2074-2078
pubmed: 34153122
Ann Dermatol. 2018 Feb;30(1):13-19
pubmed: 29386827
J Eur Acad Dermatol Venereol. 2019 May;33(5):925-929
pubmed: 30663128
BMC Psychiatry. 2020 Aug 20;20(1):411
pubmed: 32819315
Mol Vis. 2009 Jul 28;15:1449-55
pubmed: 19641634
J Invest Dermatol. 2011 Mar;131(3):637-43
pubmed: 20944650
Arch Dermatol. 1990 Jan;126(1):66-8
pubmed: 2404464
Arch Dermatol Res. 2023 Apr;315(3):419-427
pubmed: 35834038
J Am Acad Dermatol. 1981 Nov;5(5):558-60
pubmed: 7028805
Br J Dermatol. 2017 Jan;176(1):87-99
pubmed: 27343837
Adv Clin Exp Med. 2019 May;28(5):637-642
pubmed: 30784240
Br J Dermatol. 2005 Mar;152(3):537-40
pubmed: 15787824
Int J Immunopathol Pharmacol. 1999 May-Aug;12(2):55-61
pubmed: 12783647
Trans St Johns Hosp Dermatol Soc. 1968;54(2):148-51
pubmed: 5715710
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):2067-2073
pubmed: 33896070
Australas J Dermatol. 2019 Feb;60(1):23-28
pubmed: 30141189
Br J Dermatol. 2018 Jun;178(6):1462-1463
pubmed: 29478242
Front Med (Lausanne). 2018 Aug 08;5:222
pubmed: 30135860
Br J Dermatol. 2011 Sep;165(3):593-9
pubmed: 21517800
Indian J Dermatol Venereol Leprol. 2017 Mar-Apr;83(2):195-199
pubmed: 27679408
J Invest Dermatol. 2018 Jul;138(7):1659-1661
pubmed: 29427585
J Clin Med. 2021 Apr 28;10(9):
pubmed: 33925042
Orphanet J Rare Dis. 2021 May 19;16(1):228
pubmed: 34011352
Int J Mol Sci. 2020 Sep 18;21(18):
pubmed: 32961953
ISRN Endocrinol. 2013 Jun 26;2013:509764
pubmed: 23878745
JAMA Dermatol. 2022 Aug 1;158(8):933-941
pubmed: 35612829
Ther Adv Chronic Dis. 2022 Oct 15;13:20406223221130707
pubmed: 36267486
Am J Clin Dermatol. 2017 Dec;18(6):813-823
pubmed: 28534318